ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1885

Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial

Emilce Schneeberger1, Gustavo Citera2, Dario Ponce de Leon3, Annette Szumski4, Kenneth Kwok5, Mariel Cutri6 and Maxime Dougados7, 1Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3PFIZER, LIMA, Peru, 4Syneos Health, Princeton, 5Pfizer, New York, NY, 6Pfizer, Buenos Aires, Argentina, 7Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), ankylosing spondylitis disease activity score, etanercept

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic application is required for its calculation. SASDAS (simplified ASDAS) is the sum of the ASDAS´s components, which includes C-reactive protein (CRP), and is easy to perform in daily practice. The objective of this analysis was to compare the SASDAS index against the standard ASDAS index (CRP version) at baseline and post-baseline in a randomized controlled trial (EMBARK).

Methods: EMBARK assessed etanercept (ETN) 50 mg/week in early active NSAID-refractory non-radiographic axSpA patients receiving background NSAID. Subjects received ETN or placebo (PBO) for 12 weeks (double-blind) followed by ETN only (open-label). Continuous ASDAS and SASDAS were evaluated by Spearman’s Correlations, and agreement in ASDAS vs SASDAS disease categories (minimal, low, high, very high disease activity) by Cohen’s weighted kappa for individual and pooled treatments. The capacity to discriminate between treatments was evaluated by treatment effect size (ES) for ETN vs PBO at Week 12, and the sensitivity to change from baseline at Weeks 12 and 24 by ES for change.

Results: Of 215 patients in the modified intention-to-treat (mITT) population (ETN, n=106; PBO, n=109), 208 entered the open-label phase (ETN/ETN, n=102; PBO/ETN, n=106). The mean age was 32 years, 64% (ETN) and 58% (PBO) were male, and average disease duration was 2.4 (ETN) and 2.5 years (PBO). There was a strong correlation between continuous ASDAS and SASDAS. At baseline, Spearman’s correlation was 0.82 (ETN) and 0.87 (PBO); at Weeks 12 and 24 it was 0.89 (ETN), 0.90 (PBO), and 0.88 (both treatments), respectively. The evaluation of categorical SASDAS placed more patients in high or very high disease activity compared with categorical ASDAS; for example, at baseline, in the whole population, 38/213 patients (17.8%) with moderate and high disease activity by ASDAS were categorized with higher disease activity by SASDAS (20/213 moderate, 18/213 high), and 26/213 patients (12.2%) categorized with lower disease activity (3/213 moderate, 4/213 high, 19/213 very high) (Table 1). A similar pattern was seen post-baseline. Cohen’s weighted kappa statistics range from 0.54 ─ 0.73 for all individual/pooled treatments and time points, reflecting moderate-to-substantial agreement. The discriminant capacity evaluated by the treatment ES was higher with ASDAS compared with SASDAS (ES [95% CI], ASDAS: -0.74 [-1.03,-0.46]; SASDAS: -0.51 (-0.79, -0.23), but the sensitivity to change was similar (Figure 1).

Conclusion: Despite the simplicity of SASDAS, these data suggest a moderate-to-substantial agreement with ASDAS for classifying patients with active disease and a lower treatment discriminant capacity. Further evaluation of this composite index is required before implementation in daily practice and/or clinical trials.


Disclosure: E. Schneeberger, Abbvie, 1, 2, 3, Amgen, 1, 2, 3, BMS, 1, 2, 3, Genzyme, 1, 2, 3, Janssen, 1, 2, 3, Eli Lilly, 1, 2, 3, Novartis, 1, 2, 3, Pfizer, 1, 2, 3; G. Citera, AbbVie, 5, 8, Eli Lilly, 5, 8, Bristol-Myers Squibb Company, 5, 8, Gema, 5, 8, Pfizer, 5, 8, Janssen, 5, 8; D. Ponce de Leon, Pfizer, 1; A. Szumski, Syneos Health, 1; K. Kwok, Pfizer, 1, 2; M. Cutri, Pfizer, 1; M. Dougados, Pfizer, 1, 2, Abbvie, 1, 2, UCB, 1, 2, Merck, 1, 2, Lilly, 1, 2, BMS, 1, 2, Roche, 1, 2, Novartis, 1, 2.

To cite this abstract in AMA style:

Schneeberger E, Citera G, Ponce de Leon D, Szumski A, Kwok K, Cutri M, Dougados M. Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/performance-of-sasdas-simplified-axial-spondyloarthritis-disease-activity-score-versus-asdas-in-a-post-hoc-analysis-of-a-randomized-controlled-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-sasdas-simplified-axial-spondyloarthritis-disease-activity-score-versus-asdas-in-a-post-hoc-analysis-of-a-randomized-controlled-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology